Free Trial
NASDAQ:ICCC

ImmuCell Q1 2025 Earnings Report

ImmuCell logo
$4.91 -0.06 (-1.21%)
As of 05/14/2025 04:00 PM Eastern
Upcoming Event
Earnings Conference Call
ImmuCell Q1 2025
00:00 / 00:00
Live Transcript
Follow Audio

ImmuCell EPS Results

Actual EPS
$0.16
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ImmuCell Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ImmuCell Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
9:00AM ET

ImmuCell Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Top Stock Reports for Netflix, SAP & Shell
See More ImmuCell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuCell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuCell and other key companies, straight to your email.

About ImmuCell

ImmuCell (NASDAQ:ICCC), an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

View ImmuCell Profile

More Earnings Resources from MarketBeat